Franz Schaefer
Overview
Explore the profile of Franz Schaefer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
464
Citations
11354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burgmaier K, Kilian S, Arbeiter K, Atmis B, Boyer O, Buescher A, et al.
Kidney Int
. 2025 Feb;
PMID: 39922379
Autosomal recessive polycystic kidney disease (ARPKD) is a severe hepatorenal fibrocystic disorder. Its rareness and the variability of disease courses have been major obstacles for the establishment of clinical trials...
2.
Hengel F, Dehde S, Yilmaz A, Bayazit A, Ozaltin F, Paripovic D, et al.
Kidney Int
. 2025 Feb;
PMID: 39922375
Objective: Autoantibodies against the podocyte protein nephrin were recently identified in a pediatric cohort primarily comprising steroid-sensitive (SSNS) and steroid-dependent (SDNS) nephrotic syndrome (NS). However, their prevalence across all NS...
3.
Dahmer-Heath M, Gerss J, Fliser D, Liebau M, Speer T, Telgmann A, et al.
Kidney Int Rep
. 2025 Jan;
10(1):197-208.
PMID: 39810774
Introduction: Phenotypic heterogeneity and unpredictability of individual disease progression present enormous challenges in ultrarare renal ciliopathies. The tubular-derived glycoprotein, Dickkopf-related protein 3 (DKK3) is a promising biomarker for kidney fibrosis...
4.
Wlodkowski T, Haeberle S, Schaefer F
Inn Med (Heidelb)
. 2024 Nov;
65(12):1283-1292.
PMID: 39538006
Rare kidney diseases encompass a wide range of congenital, inherited and acquired conditions. Two million Europeans are affected by rare kidney diseases. The European Rare Kidney Disease Reference Network (ERKNet)...
5.
El Mikati I, Begin B, Borzych-Duzalka D, Neu A, Richardson T, Same R, et al.
J Clin Epidemiol
. 2024 Oct;
177:111578.
PMID: 39442676
Objectives: Trustworthy guidelines rely on systematic reviews of the best available published evidence. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) Working Group has provided guidance about developing evidence-based...
6.
Hari P, Khandelwal P, Boyer O, Bhimma R, Cano F, Christian M, et al.
Pediatr Nephrol
. 2024 Oct;
40(3):865-872.
PMID: 39384644
Assessment of the true impact of therapeutic interventions is a challenge in the absence of universal, standardized definitions for clinical trial endpoints in children with kidney diseases. Steroid-resistant nephrotic syndrome...
7.
Warady B, Same R, Borzych-Duzalka D, Neu A, El Mikati I, Mustafa R, et al.
Perit Dial Int
. 2024 Sep;
44(5):303-364.
PMID: 39313225
Infection-related complications remain the most significant cause for morbidity and technique failure in infants, children and adolescents who receive maintenance peritoneal dialysis (PD). The 2024 update of the Clinical Practice...
8.
Thumfart J, Wagner S, Kirchner M, Azukaitis K, Bayazit A, Obrycki L, et al.
Kidney Int Rep
. 2024 Sep;
9(9):2750-2758.
PMID: 39291215
Introduction: The choice and timing of kidney replacement therapy (KRT) is influenced by clinical factors, laboratory features, feasibility issues, family preferences, and clinicians' attitudes. We analyzed the factors associated with...
9.
Schaefer F, Al-Dakkak I, Anokhina K, Cohen D, Greenbaum L, Ariceta G
Kidney Int Rep
. 2024 Sep;
9(9):2648-2656.
PMID: 39291212
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive rare disease that, if untreated, can result in severe organ damage and death. Ravulizumab, a next-generation terminal complement inhibitor, provides immediate,...
10.
Wang C, Whiting A, Rath A, Anido R, Ardigo D, Baynam G, et al.
Orphanet J Rare Dis
. 2024 Sep;
19(1):334.
PMID: 39261914
Improving health and social equity for persons living with a rare disease (PLWRD) is increasingly recognized as a global policy priority. However, there is currently no international alignment on how...